Graph Therapeutics offers an AI‑driven precision immunology platform that combines high‑throughput perturbation experiments on primary patient immune cells with multi‑omics profiling. By applying machine‑learning models to these systematic datasets, the company identifies disease‑relevant pathways, therapeutic targets, and predictive biomarkers for inflammatory and autoimmune conditions, enabling the development of targeted therapies and companion diagnostics for pharmaceutical and biotech partners.
Funding
Funding not disclosed
Founders
Product
Problem
Current drug discovery for immune-mediated diseases suffers from limited insight into patient-specific cellular responses, making it difficult to identify effective targets and predictive biomarkers. This hampers the development of therapies that address the heterogeneity and complexity of inflammatory and autoimmune conditions.
Solution
Graph Therapeutics addresses this gap with an AI‑driven precision immunology platform that combines perturbation experiments on primary patient cell samples with multi‑omics profiling. The platform generates large, systematic datasets of how immune cells respond to diverse perturbations, which are then analyzed using machine‑learning models to uncover disease‑relevant pathways, therapeutic targets, and biomarkers. By integrating laboratory‑in‑the‑loop experimentation with computational analysis, the system enables iterative target discovery and validation that is directly grounded in patient biology. The resulting insights can be translated into targeted therapies and companion diagnostics for immune‑driven diseases.
Target Audience
Primary customers are pharmaceutical and biotech companies developing treatments for inflammatory, autoimmune, and other immune‑mediated diseases, as well as academic research groups focused on immunology and precision medicine.
Features
- Lab‑in‑the‑loop perturbation workflow that screens hundreds of millions of primary immune cells under systematic conditions
- Multi‑omics integration (genomics, transcriptomics, proteomics, epigenomics) to capture comprehensive cellular states
- AI/ML pipelines that model perturbation responses, identify causal networks, and prioritize drug targets
- Scalable data generation platform partnered with Parse’s GigLab for high‑throughput immune cell profiling
- Collaborative framework with academic and industry partners to accelerate precision immunology research
- Generation of clinically relevant biomarkers linked to therapeutic response and disease progression